A Clinical Trial About Treatment of Mild to Moderate Persistent Alergic Rhinnitis With Test or Reference Mometasone (PUMA)

Inclusion Criteria: * Sign and date the informed consent form or, in case of subjects younger than 18 years, the document must also be signed by a legal guardian; * ≥ 12 years old; * Suffer from mild to moderated persistent alergic rhinitis; * Total NIS scale score ≥ 4 points at the screening visit and within at least 4 of the 7 days before the randomization visit; * Indication for use nasal corticosteroid; * Present with alergic rhinitis symptoms for at least 2 years; * May undergo a washout period of at least 2 weeks Exclusion Criteria: * Patients with severe alergic rhinitis; * Patients with severe co-morbidities (at the investigator's criteria); * Patients with mild to severe persistent asthma; * Clinical history of infection of the airways 30 days before the study entry; * Patients with structural changes causing nasal obstruction, such as pronounced nasal septum deviation, nasal polyps or any other type of nasal malformation; * For female subjects, be pregnant or breastfeeding or planning to become pregnant or unwilling to use safe birth control methods during the study; * subjects in need of other drugs to treat alergic rhinitis, such as anti-immunoglobulin E, immunotherapy, anti-leukotrienes, oral corticosteroids, inhalant corticosteroids, or any administration route other than cutaneous; * Active smokers (use of cigarette, pipe, cigar or any other form of tobacco in any amount within the past 3 months before the study entry); * Participation in another clinical study within the past 12 months;